ARTV

3.7801.31%
BF

Brian F. Daniels

Independent Chairman of the Board

Dr. Brian F. Daniels, M.D., is Independent Non-executive Director of CSL Limited from December 1, 2024. Dr. Daniels serves as Member of Scientific Advisory Board at Soteria Biotherapeutics, Inc. He serves as Director at Neurogastrx, Inc. He served as Member of Scientific Advisory Board of Gradalis, Inc. He served as Member of Scientific Advisory Board of IDEAYA Biosciences, Inc. until 2022. Dr. Daniels served as an Independent Director at Novo Nordisk A/S since March 2016 until March 25, 2021. He served as Member of Scientific Advisory Board at Cabaletta Bio, Inc. since June 24, 2021 until June 2025. He serves on the Board of Inipharm Inc. from November 2020. He serves as an Independent Chairman of the Board of Artiva Biotherapeutics, Inc. since June 2020. He served as Member of Scientific Advisory Board at Biocon Limited. Dr. Daniels had been an Independent Director of Cabaletta Bio, Inc. since October 2018 until June 24, 2021. Dr. Daniels serves as Venture Partner at 5AM Venture Management LLC since 2025. Dr. Daniels serves as Partner at 5AM Venture Management LLC since 2018, previously served as Venture Partner since joining the firm on November 11, 2014 until 2018. He is as Director and Former SVP, Global Development and Medical Affairs, Bristol-Myers Squibb. Dr. Daniels serves as a Senior Advisor with BCG. He served as Senior Vice President of Global Development and Medical Affairs and Research and Development of Bristol-Myers Squibb Co. from March 2008 to July 1, 2014. He served as Senior Vice President of Global Clinical Development, Research and Development, a division of Bristol-Myers Squibb Co. from 2004 to 2008. He held positions directing and conducting clinical research at Merck Research Laboratories and at Genentech. He served as a Member of Management Council at Bristol-Myers Squibb Company. Dr. Daniels is a Director at these 5AM companies: Spyryx Bioscience, Inipharm Inc., Nohla Therapeutics, Rarecyte and Ideaya Biosciences (independent). He leads the Clinical Advisory Board for Aprea Therapeutics and also served on the Scientific Advisory Board of Novira. He was Member of Scientific Advisory Board at TRACON Pharmaceuticals, Inc. since December 4, 2017. He also serves as the Director of Medarex, Inc. He has experience in clinical development, medical affairs and corporate strategy across a broad range of therapeutic areas. He volunteers his time at The Gladstone Institutes at the University of California in San Francisco as a translational Partner. He completed residency programs in Internal Medicine at The New York Hospital of Cornell Medical College in New York and in Rheumatology at the University of California, San Francisco. He served as Director of RareCyte, Inc. until 2020. He completed his residency in internal medicine at New York Hospital and a fellowship in rheumatology and immunology at University of California, San Francisco. Dr. Daniels received his B.S. and M.S. degrees from Massachusetts Institute of Technology and his M.D. from Washington University in St. Louis.

Positions